Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 47 citing articles:

Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 113
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
Aruni Ghose, Sri Vidya Niharika Gullapalli, Naila Chohan, et al.
Proteomes (2022) Vol. 10, Iss. 2, pp. 16-16
Open Access | Times Cited: 103
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 27
Recent strategies to overcome breast cancer resistance
Muhammad Muzamil Khan, Satya Siva Kishan Yalamarty, Bharat Ashok Rajmalani, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104351-104351
Open Access | Times Cited: 18
Design, synthesis and biological evaluation of dual CDK9/PARP inhibitors for the treatment of cancer
Jindi Huang, Ya He, Sumeng Chen, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117367-117367
Closed Access | Times Cited: 3
Tailored therapies for triple-negative breast cancer: current landscape and future perceptions
Yumna Khan, Sana Rizvi, Ali Raza, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 2
CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies
Zhipu Niu, Jingyuan Wu, Qiancheng Zhao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, et al.
Cancer Research (2023) Vol. 83, Iss. 19, pp. 3264-3283
Open Access | Times Cited: 22
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes BesidesBRCA1andBRCA2as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
Ioannis A. Voutsadakis, Athina Stravodimou
Anticancer Research (2023) Vol. 43, Iss. 3, pp. 967-981
Open Access | Times Cited: 19
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Matías A. Bustos, Takamichi Yokoe, Yoshiaki Shoji, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Fang Liu, Jia‐Shu Chen, Xiangqian Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 24, pp. 16464-16483
Closed Access | Times Cited: 11
Nucleic acid vaccines‐based therapy for triple‐negative breast cancer: A new paradigm in tumor immunotherapy arena
Raed Obaid Saleh, Fatma M. Ibrahim, Harikumar Pallathadka, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 3
Closed Access | Times Cited: 4
Ovarian cancer: Diagnosis and treatment strategies (Review)
Xuejiao Li, LI Zhuo-cheng, Huiling Ma, et al.
Oncology Letters (2024) Vol. 28, Iss. 3
Open Access | Times Cited: 4
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
Trudy Janice Philips, Britt Erickson, Stefani N. Thomas
Frontiers in Oncology (2025) Vol. 14
Open Access
PARP‐1 Inhibition Increases Oxidative Stress in Ets‐1‐Expressing MDA‐MB‐231 Breast Cancer Cells
Magalie Hervieu, Arnaud J. Legrand, Emilie Floquet, et al.
Cancer Reports (2025) Vol. 8, Iss. 1
Open Access
A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis
Shiya Ji, Lu Chen, Y L Yu, et al.
Journal of Ovarian Research (2025) Vol. 18, Iss. 1
Open Access
Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors
Mahmoud A. El Hassab, Wagdy M. Eldehna, Ghaneya S. Hassan, et al.
BMC Chemistry (2025) Vol. 19, Iss. 1
Open Access
IGF1R-Targeted Delivery of a Bridged Nucleic Acid Oligonucleotide-Peptide Conjugate for MicroRNA 21 Inhibition in Triple-Negative Breast Cancer
Juncheng Yu, Vilas Desai, Jason Mazzaroth, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis
Sajjad Hajihosseini, Elham Emami, Seyed Rasoul Zakavi, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Hao Li, Ying Chang, Tiefeng Jin, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Genetic characterization of BRCA1 and BRCA2 variants in cancer and high-risk family screening cohorts in the UAE population
Ayesha Ali, Mahabbat Ali, Dalia El-Shourbagy, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 4
Open Access
Discovery of a Novel [6–6–5–5–6] Pentacyclic Tetrahydrocyclopentaphthalazinone as a Promising PARP Inhibitor Scaffold
Yagmur U. Doruk, Morgan E. Diolaiti, Alan Ashworth, et al.
ACS Medicinal Chemistry Letters (2025)
Closed Access
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Michael T. Schweizer, Roman Gulati, Todd Yezefski, et al.
Prostate Cancer and Prostatic Diseases (2022) Vol. 26, Iss. 1, pp. 194-200
Open Access | Times Cited: 15
Cellular Responses to Widespread DNA Replication Stress
Jac A. Nickoloff, Aruna S. Jaiswal, Neelam Sharma, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16903-16903
Open Access | Times Cited: 9
Bufotalin Suppresses Proliferation and Metastasis of Triple-Negative Breast Cancer Cells by Promoting Apoptosis and Inhibiting the STAT3/EMT Axis
So Park, Hye Jin Jung
Molecules (2023) Vol. 28, Iss. 19, pp. 6783-6783
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top